Zevra Therapeutics, Inc. (ZVRA) 股票分析

公司概述

Zevra Therapeutics, Inc. operates as a commercial-stage biotechnology company dedicated to addressing unmet medical needs for the treatment of rare diseases within the United States market. The firm utilizes its proprietary Ligand Activated Technology platform to develop its product pipeline, with KP1077 serving as the primary product candidate in its current portfolio. This specialized business model positions the company within the broader Healthcare sector, specifically focusing on the high-potential but complex Biotechnology industry where innovation drives value creation. In terms of scale, the company holds a market capitalization of $563.04M and reported annual revenue of $106.47M while employing a workforce of 61 individuals. These financial dimensions indicate that Zevra Therapeutics possesses a mid-sized market valuation relative to its revenue generation, suggesting a capital-intensive growth stage typical for biotechnology firms that prioritize research and development expenditures over immediate profitability scaling.

财务健康

The company generated revenue of $106.47M over the trailing twelve months and recorded a net income of $77.58M, alongside an EBITDA figure of $-179,000. The significant divergence between the positive net income of $77.58M and the negative EBITDA of $-179,000 reveals a cost structure where non-operating income or significant tax benefits, likely due to research and development tax credits common in the biotech sector, are driving overall profitability despite negative core earnings before interest, taxes, depreciation, and amortization. Free cash flow stands at $-1,955,250, indicating that the company is currently consuming cash to fund its operations and growth initiatives rather than generating surplus liquidity for distribution to shareholders or debt reduction. The gross margin is reported at 84.5%, reflecting the high-margin nature of biotechnology sales once manufacturing costs are covered, while the operating margin sits at 27.3% and the profit margin reaches 78.2%, highlighting an efficient conversion of revenue to bottom-line profit despite the EBITDA deficit. The balance sheet shows a cash position of $191.01M against total debt of $63.21M, resulting in a debt-to-equity ratio of 40.87, which suggests a leveraged balance sheet where debt obligations are substantial relative to shareholder equity. However, the current ratio of 5.68 indicates robust short-term liquidity, as the company holds significantly more current assets than current liabilities, providing ample buffer to meet its immediate financial obligations. Return on Equity is calculated at 85.7%, demonstrating high returns generated on shareholders' capital, whereas Return on Assets is -1.1%, signaling that the total asset base is currently generating a negative return on a consolidated basis, a pattern often seen in asset-heavy or R&D-intensive biotechnology companies.

估值评估

Zevra Therapeutics, Inc. trades with a trailing P/E ratio of 7.10 and a forward P/E of 6.31, implying that the market expects earnings to increase in the future as the forward multiple is lower than the trailing multiple, suggesting an anticipated improvement in profitability metrics. The price-to-book ratio is 3.53, indicating that the stock is trading at a significant premium over its net asset value, which is typical for biotechnology firms where the value of the intellectual property and pipeline outweighs the book value of tangible assets. Alternative valuation metrics include a price-to-sales ratio of 5.29 and an EV/EBITDA of -2431.50, where the extremely negative EV/EBITDA reflects the company's negative EBITDA position and underscores the challenges in valuing the firm based on traditional cash flow multiples. The stock has seen a 52-week high of $13.16 and a 52-week low of $6.19, meaning the current price sits within this historical trading range, reflecting recent market volatility specific to the healthcare sector. The beta value is 0.89, which indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market fluctuations compared to the average large-cap stock.

Growth & Income

Revenue growth over the last year is reported at 183.4%, while earnings growth is listed as N/A, indicating that the company is in an early growth phase where top-line expansion is outpacing traditional earnings metrics due to the lag in recognizing net income relative to revenue. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all generated earnings are effectively reinvested into the company's operations, research, and product development rather than being distributed to shareholders. This reinvestment strategy aligns with the commercial-stage nature of the business, where capital is prioritized for advancing the Ligand Activated Technology platform and bringing lead candidates like KP1077 to market. The overall growth and income profile is characterized by aggressive top-line expansion without dividend income, reflecting a capital allocation strategy focused on long-term asset building and market penetration within the rare disease therapeutic area.